カテゴリ： 世界, 医療/バイオ, Market Monitor Global

抗VEGT薬のグローバル市場展望 2023年-2029年：チロシンキナーゼ阻害剤、モノクローナル抗体、その他

■ 英語タイトル：Anti-VEGT Drugs Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23DC14227）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23DC14227
■ 発行日：2023年12月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品
■ ページ数：79
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[抗VEGT薬のグローバル市場展望 2023年-2029年：チロシンキナーゼ阻害剤、モノクローナル抗体、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の抗VEGT薬市場規模と予測を収録しています。・世界の抗VEGT薬市場：売上、2018年-2023年、2024年-2029年
・世界の抗VEGT薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の抗VEGT薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「チロシンキナーゼ阻害剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

抗VEGT薬のグローバル主要企業は、Genentech (Roche)、 Regeneron Pharmaceuticals、 Novartis、 AstraZeneca、 Bayer、 Abbott、 Santen、 Pfizer、 Sanofi、 Bristol-Myers Squibb、 GlaxoSmithKline、 Eli Lilly & Company、 Chugai Pharma、 Kanghong Pharmaceuticalなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、抗VEGT薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の抗VEGT薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の抗VEGT薬市場：タイプ別市場シェア、2022年
・チロシンキナーゼ阻害剤、モノクローナル抗体、その他

世界の抗VEGT薬市場：用途別、2018年-2023年、2024年-2029年
世界の抗VEGT薬市場：用途別市場シェア、2022年
・腫瘍、眼科、その他

世界の抗VEGT薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の抗VEGT薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における抗VEGT薬のグローバル売上、2018年-2023年
・主要企業における抗VEGT薬のグローバル売上シェア、2022年
・主要企業における抗VEGT薬のグローバル販売量、2018年-2023年
・主要企業における抗VEGT薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Genentech (Roche)、 Regeneron Pharmaceuticals、 Novartis、 AstraZeneca、 Bayer、 Abbott、 Santen、 Pfizer、 Sanofi、 Bristol-Myers Squibb、 GlaxoSmithKline、 Eli Lilly & Company、 Chugai Pharma、 Kanghong Pharmaceutical

*************************************************************

・調査・分析レポートの概要
抗VEGT薬市場の定義
市場セグメント
世界の抗VEGT薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の抗VEGT薬市場規模
世界の抗VEGT薬市場規模：2022年 VS 2029年
世界の抗VEGT薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの抗VEGT薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の抗VEGT薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：チロシンキナーゼ阻害剤、モノクローナル抗体、その他
抗VEGT薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：腫瘍、眼科、その他
抗VEGT薬の用途別グローバル売上・予測

・地域別市場分析
地域別抗VEGT薬市場規模 2022年と2029年
地域別抗VEGT薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Genentech (Roche)、 Regeneron Pharmaceuticals、 Novartis、 AstraZeneca、 Bayer、 Abbott、 Santen、 Pfizer、 Sanofi、 Bristol-Myers Squibb、 GlaxoSmithKline、 Eli Lilly & Company、 Chugai Pharma、 Kanghong Pharmaceutical
...

This research report provides a comprehensive analysis of the Anti-VEGT Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Anti-VEGT Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Anti-VEGT Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Anti-VEGT Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Anti-VEGT Drugs market presents opportunities for various stakeholders, including Oncology, Ophthalmology. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Anti-VEGT Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Anti-VEGT Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Anti-VEGT Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Anti-VEGT Drugs market.
Market Overview: The report provides a comprehensive overview of the Anti-VEGT Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Tyrosine Kinase Inhibitors, Monoclonal Antibodies), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Anti-VEGT Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Anti-VEGT Drugs market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Anti-VEGT Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Anti-VEGT Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Anti-VEGT Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Anti-VEGT Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Anti-VEGT Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Anti-VEGT Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Anti-VEGT Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Market segment by Application
Oncology
Ophthalmology
Others
Global Anti-VEGT Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Genentech (Roche)
Regeneron Pharmaceuticals
Novartis
AstraZeneca
Bayer
Abbott
Santen
Pfizer
Sanofi
Bristol-Myers Squibb
GlaxoSmithKline
Eli Lilly & Company
Chugai Pharma
Kanghong Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Anti-VEGT Drugs, market overview.
Chapter 2: Global Anti-VEGT Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Anti-VEGT Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-VEGT Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Anti-VEGT Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Anti-VEGT Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Anti-VEGT Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Anti-VEGT Drugs Overall Market Size
2.1 Global Anti-VEGT Drugs Market Size: 2022 VS 2029
2.2 Global Anti-VEGT Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Anti-VEGT Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Anti-VEGT Drugs Players in Global Market
3.2 Top Global Anti-VEGT Drugs Companies Ranked by Revenue
3.3 Global Anti-VEGT Drugs Revenue by Companies
3.4 Global Anti-VEGT Drugs Sales by Companies
3.5 Global Anti-VEGT Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Anti-VEGT Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Anti-VEGT Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Anti-VEGT Drugs Players in Global Market
3.8.1 List of Global Tier 1 Anti-VEGT Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Anti-VEGT Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Anti-VEGT Drugs Market Size Markets, 2022 & 2029
4.1.2 Tyrosine Kinase Inhibitors
4.1.3 Monoclonal Antibodies
4.1.4 Others
4.2 By Type – Global Anti-VEGT Drugs Revenue & Forecasts
4.2.1 By Type – Global Anti-VEGT Drugs Revenue, 2018-2023
4.2.2 By Type – Global Anti-VEGT Drugs Revenue, 2024-2029
4.2.3 By Type – Global Anti-VEGT Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Anti-VEGT Drugs Sales & Forecasts
4.3.1 By Type – Global Anti-VEGT Drugs Sales, 2018-2023
4.3.2 By Type – Global Anti-VEGT Drugs Sales, 2024-2029
4.3.3 By Type – Global Anti-VEGT Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Anti-VEGT Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Anti-VEGT Drugs Market Size, 2022 & 2029
5.1.2 Oncology
5.1.3 Ophthalmology
5.1.4 Others
5.2 By Application – Global Anti-VEGT Drugs Revenue & Forecasts
5.2.1 By Application – Global Anti-VEGT Drugs Revenue, 2018-2023
5.2.2 By Application – Global Anti-VEGT Drugs Revenue, 2024-2029
5.2.3 By Application – Global Anti-VEGT Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Anti-VEGT Drugs Sales & Forecasts
5.3.1 By Application – Global Anti-VEGT Drugs Sales, 2018-2023
5.3.2 By Application – Global Anti-VEGT Drugs Sales, 2024-2029
5.3.3 By Application – Global Anti-VEGT Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Anti-VEGT Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Anti-VEGT Drugs Market Size, 2022 & 2029
6.2 By Region – Global Anti-VEGT Drugs Revenue & Forecasts
6.2.1 By Region – Global Anti-VEGT Drugs Revenue, 2018-2023
6.2.2 By Region – Global Anti-VEGT Drugs Revenue, 2024-2029
6.2.3 By Region – Global Anti-VEGT Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Anti-VEGT Drugs Sales & Forecasts
6.3.1 By Region – Global Anti-VEGT Drugs Sales, 2018-2023
6.3.2 By Region – Global Anti-VEGT Drugs Sales, 2024-2029
6.3.3 By Region – Global Anti-VEGT Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Anti-VEGT Drugs Revenue, 2018-2029
6.4.2 By Country – North America Anti-VEGT Drugs Sales, 2018-2029
6.4.3 US Anti-VEGT Drugs Market Size, 2018-2029
6.4.4 Canada Anti-VEGT Drugs Market Size, 2018-2029
6.4.5 Mexico Anti-VEGT Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Anti-VEGT Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Anti-VEGT Drugs Sales, 2018-2029
6.5.3 Germany Anti-VEGT Drugs Market Size, 2018-2029
6.5.4 France Anti-VEGT Drugs Market Size, 2018-2029
6.5.5 U.K. Anti-VEGT Drugs Market Size, 2018-2029
6.5.6 Italy Anti-VEGT Drugs Market Size, 2018-2029
6.5.7 Russia Anti-VEGT Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Anti-VEGT Drugs Market Size, 2018-2029
6.5.9 Benelux Anti-VEGT Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Anti-VEGT Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Anti-VEGT Drugs Sales, 2018-2029
6.6.3 China Anti-VEGT Drugs Market Size, 2018-2029
6.6.4 Japan Anti-VEGT Drugs Market Size, 2018-2029
6.6.5 South Korea Anti-VEGT Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Anti-VEGT Drugs Market Size, 2018-2029
6.6.7 India Anti-VEGT Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Anti-VEGT Drugs Revenue, 2018-2029
6.7.2 By Country – South America Anti-VEGT Drugs Sales, 2018-2029
6.7.3 Brazil Anti-VEGT Drugs Market Size, 2018-2029
6.7.4 Argentina Anti-VEGT Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Anti-VEGT Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Anti-VEGT Drugs Sales, 2018-2029
6.8.3 Turkey Anti-VEGT Drugs Market Size, 2018-2029
6.8.4 Israel Anti-VEGT Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Anti-VEGT Drugs Market Size, 2018-2029
6.8.6 UAE Anti-VEGT Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Genentech (Roche)
7.1.1 Genentech (Roche) Company Summary
7.1.2 Genentech (Roche) Business Overview
7.1.3 Genentech (Roche) Anti-VEGT Drugs Major Product Offerings
7.1.4 Genentech (Roche) Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Genentech (Roche) Key News & Latest Developments
7.2 Regeneron Pharmaceuticals
7.2.1 Regeneron Pharmaceuticals Company Summary
7.2.2 Regeneron Pharmaceuticals Business Overview
7.2.3 Regeneron Pharmaceuticals Anti-VEGT Drugs Major Product Offerings
7.2.4 Regeneron Pharmaceuticals Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Regeneron Pharmaceuticals Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Anti-VEGT Drugs Major Product Offerings
7.3.4 Novartis Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Company Summary
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca Anti-VEGT Drugs Major Product Offerings
7.4.4 AstraZeneca Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.4.5 AstraZeneca Key News & Latest Developments
7.5 Bayer
7.5.1 Bayer Company Summary
7.5.2 Bayer Business Overview
7.5.3 Bayer Anti-VEGT Drugs Major Product Offerings
7.5.4 Bayer Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Bayer Key News & Latest Developments
7.6 Abbott
7.6.1 Abbott Company Summary
7.6.2 Abbott Business Overview
7.6.3 Abbott Anti-VEGT Drugs Major Product Offerings
7.6.4 Abbott Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Abbott Key News & Latest Developments
7.7 Santen
7.7.1 Santen Company Summary
7.7.2 Santen Business Overview
7.7.3 Santen Anti-VEGT Drugs Major Product Offerings
7.7.4 Santen Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Santen Key News & Latest Developments
7.8 Pfizer
7.8.1 Pfizer Company Summary
7.8.2 Pfizer Business Overview
7.8.3 Pfizer Anti-VEGT Drugs Major Product Offerings
7.8.4 Pfizer Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Pfizer Key News & Latest Developments
7.9 Sanofi
7.9.1 Sanofi Company Summary
7.9.2 Sanofi Business Overview
7.9.3 Sanofi Anti-VEGT Drugs Major Product Offerings
7.9.4 Sanofi Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Sanofi Key News & Latest Developments
7.10 Bristol-Myers Squibb
7.10.1 Bristol-Myers Squibb Company Summary
7.10.2 Bristol-Myers Squibb Business Overview
7.10.3 Bristol-Myers Squibb Anti-VEGT Drugs Major Product Offerings
7.10.4 Bristol-Myers Squibb Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Bristol-Myers Squibb Key News & Latest Developments
7.11 GlaxoSmithKline
7.11.1 GlaxoSmithKline Company Summary
7.11.2 GlaxoSmithKline Business Overview
7.11.3 GlaxoSmithKline Anti-VEGT Drugs Major Product Offerings
7.11.4 GlaxoSmithKline Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.11.5 GlaxoSmithKline Key News & Latest Developments
7.12 Eli Lilly & Company
7.12.1 Eli Lilly & Company Company Summary
7.12.2 Eli Lilly & Company Business Overview
7.12.3 Eli Lilly & Company Anti-VEGT Drugs Major Product Offerings
7.12.4 Eli Lilly & Company Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.12.5 Eli Lilly & Company Key News & Latest Developments
7.13 Chugai Pharma
7.13.1 Chugai Pharma Company Summary
7.13.2 Chugai Pharma Business Overview
7.13.3 Chugai Pharma Anti-VEGT Drugs Major Product Offerings
7.13.4 Chugai Pharma Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.13.5 Chugai Pharma Key News & Latest Developments
7.14 Kanghong Pharmaceutical
7.14.1 Kanghong Pharmaceutical Company Summary
7.14.2 Kanghong Pharmaceutical Business Overview
7.14.3 Kanghong Pharmaceutical Anti-VEGT Drugs Major Product Offerings
7.14.4 Kanghong Pharmaceutical Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.14.5 Kanghong Pharmaceutical Key News & Latest Developments
8 Global Anti-VEGT Drugs Production Capacity, Analysis
8.1 Global Anti-VEGT Drugs Production Capacity, 2018-2029
8.2 Anti-VEGT Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Anti-VEGT Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Anti-VEGT Drugs Supply Chain Analysis
10.1 Anti-VEGT Drugs Industry Value Chain
10.2 Anti-VEGT Drugs Upstream Market
10.3 Anti-VEGT Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Anti-VEGT Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Anti-VEGT Drugs in Global Market
Table 2. Top Anti-VEGT Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Anti-VEGT Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Anti-VEGT Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Anti-VEGT Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Anti-VEGT Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Anti-VEGT Drugs Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Anti-VEGT Drugs Product Type
Table 9. List of Global Tier 1 Anti-VEGT Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Anti-VEGT Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Anti-VEGT Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Anti-VEGT Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Anti-VEGT Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Anti-VEGT Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Anti-VEGT Drugs Sales (K Units), 2024-2029
Table 16. By Application – Global Anti-VEGT Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Anti-VEGT Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Anti-VEGT Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Anti-VEGT Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Anti-VEGT Drugs Sales (K Units), 2024-2029
Table 21. By Region – Global Anti-VEGT Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Anti-VEGT Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Anti-VEGT Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Anti-VEGT Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Anti-VEGT Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Anti-VEGT Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Anti-VEGT Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Anti-VEGT Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Anti-VEGT Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Anti-VEGT Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Anti-VEGT Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Anti-VEGT Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Anti-VEGT Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Anti-VEGT Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Anti-VEGT Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Anti-VEGT Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Anti-VEGT Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Anti-VEGT Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Anti-VEGT Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Anti-VEGT Drugs Sales, (K Units), 2024-2029
Table 46. Genentech (Roche) Company Summary
Table 47. Genentech (Roche) Anti-VEGT Drugs Product Offerings
Table 48. Genentech (Roche) Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Genentech (Roche) Key News & Latest Developments
Table 50. Regeneron Pharmaceuticals Company Summary
Table 51. Regeneron Pharmaceuticals Anti-VEGT Drugs Product Offerings
Table 52. Regeneron Pharmaceuticals Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Regeneron Pharmaceuticals Key News & Latest Developments
Table 54. Novartis Company Summary
Table 55. Novartis Anti-VEGT Drugs Product Offerings
Table 56. Novartis Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Novartis Key News & Latest Developments
Table 58. AstraZeneca Company Summary
Table 59. AstraZeneca Anti-VEGT Drugs Product Offerings
Table 60. AstraZeneca Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. AstraZeneca Key News & Latest Developments
Table 62. Bayer Company Summary
Table 63. Bayer Anti-VEGT Drugs Product Offerings
Table 64. Bayer Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Bayer Key News & Latest Developments
Table 66. Abbott Company Summary
Table 67. Abbott Anti-VEGT Drugs Product Offerings
Table 68. Abbott Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Abbott Key News & Latest Developments
Table 70. Santen Company Summary
Table 71. Santen Anti-VEGT Drugs Product Offerings
Table 72. Santen Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Santen Key News & Latest Developments
Table 74. Pfizer Company Summary
Table 75. Pfizer Anti-VEGT Drugs Product Offerings
Table 76. Pfizer Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Pfizer Key News & Latest Developments
Table 78. Sanofi Company Summary
Table 79. Sanofi Anti-VEGT Drugs Product Offerings
Table 80. Sanofi Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Sanofi Key News & Latest Developments
Table 82. Bristol-Myers Squibb Company Summary
Table 83. Bristol-Myers Squibb Anti-VEGT Drugs Product Offerings
Table 84. Bristol-Myers Squibb Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Bristol-Myers Squibb Key News & Latest Developments
Table 86. GlaxoSmithKline Company Summary
Table 87. GlaxoSmithKline Anti-VEGT Drugs Product Offerings
Table 88. GlaxoSmithKline Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. GlaxoSmithKline Key News & Latest Developments
Table 90. Eli Lilly & Company Company Summary
Table 91. Eli Lilly & Company Anti-VEGT Drugs Product Offerings
Table 92. Eli Lilly & Company Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Eli Lilly & Company Key News & Latest Developments
Table 94. Chugai Pharma Company Summary
Table 95. Chugai Pharma Anti-VEGT Drugs Product Offerings
Table 96. Chugai Pharma Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. Chugai Pharma Key News & Latest Developments
Table 98. Kanghong Pharmaceutical Company Summary
Table 99. Kanghong Pharmaceutical Anti-VEGT Drugs Product Offerings
Table 100. Kanghong Pharmaceutical Anti-VEGT Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 101. Kanghong Pharmaceutical Key News & Latest Developments
Table 102. Anti-VEGT Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 103. Global Anti-VEGT Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 104. Global Anti-VEGT Drugs Production by Region, 2018-2023 (K Units)
Table 105. Global Anti-VEGT Drugs Production by Region, 2024-2029 (K Units)
Table 106. Anti-VEGT Drugs Market Opportunities & Trends in Global Market
Table 107. Anti-VEGT Drugs Market Drivers in Global Market
Table 108. Anti-VEGT Drugs Market Restraints in Global Market
Table 109. Anti-VEGT Drugs Raw Materials
Table 110. Anti-VEGT Drugs Raw Materials Suppliers in Global Market
Table 111. Typical Anti-VEGT Drugs Downstream
Table 112. Anti-VEGT Drugs Downstream Clients in Global Market
Table 113. Anti-VEGT Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Anti-VEGT Drugs Segment by Type in 2022
Figure 2. Anti-VEGT Drugs Segment by Application in 2022
Figure 3. Global Anti-VEGT Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Anti-VEGT Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Anti-VEGT Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Anti-VEGT Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Anti-VEGT Drugs Revenue in 2022
Figure 9. By Type - Global Anti-VEGT Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Anti-VEGT Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Anti-VEGT Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Anti-VEGT Drugs Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Anti-VEGT Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Anti-VEGT Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Anti-VEGT Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Anti-VEGT Drugs Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Anti-VEGT Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Anti-VEGT Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Anti-VEGT Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Anti-VEGT Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Anti-VEGT Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Anti-VEGT Drugs Sales Market Share, 2018-2029
Figure 23. US Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Anti-VEGT Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Anti-VEGT Drugs Sales Market Share, 2018-2029
Figure 28. Germany Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Anti-VEGT Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Anti-VEGT Drugs Sales Market Share, 2018-2029
Figure 37. China Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Anti-VEGT Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Anti-VEGT Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Anti-VEGT Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Anti-VEGT Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Anti-VEGT Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Anti-VEGT Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Anti-VEGT Drugs by Region, 2022 VS 2029
Figure 54. Anti-VEGT Drugs Industry Value Chain
Figure 55. Marketing Channels


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 抗ネスチン抗体のグローバル市場展望 2023年-2029年：モノクローナル抗体、ポリクローナル抗体
  • 腎臓がん治療薬のグローバル市場展望 2023年-2029年：血管新生阻害剤、mTOR阻害剤、モノクローナル抗体、サイトカイン免疫療法（IL-2）
  • 抗Olig2抗体のグローバル市場展望 2023年-2029年：モノクローナル抗体、ポリクローナル抗体
  • 抗ニューロピリン-1抗体のグローバル市場展望 2023年-2029年：モノクローナル抗体、ポリクローナル抗体
  • 医薬品用発酵エンジニアリングのグローバル市場展望 2023年-2029年：モノクローナル抗体、抗生物質、インスリン、ヒト成長ホルモン、医薬品アミノ酸、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23DC14227 )"抗VEGT薬のグローバル市場展望 2023年-2029年：チロシンキナーゼ阻害剤、モノクローナル抗体、その他" (英文：Anti-VEGT Drugs Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。